Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGN523 in relapsed or refractory AML
NCT02040506Phase 1Completed
- Sponsor
- Igenica Biotherapeutics
- Start
- Feb 2014
- Primary completion
- Mar 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IGN523 in acute myeloid leukemia (AML), sponsored by Igenica Biotherapeutics. Primary endpoint: Incidence of adverse events. Started Feb 2014; status: completed.
02
Drugs
IGN523
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02040506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02040506.